


Abergel A, Hezode C, Asselah T. A phase 3, global, multicenter, open-label study to investigate the efficacy of elbasvir/grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis: STREAGER. The International Liver Congress. Paris, France; 2018.


Asselah T, Hassanian T, Qadish RB, et. A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis. Journal of Hepatology. 2015;62(S861).


Bari K, Luckett K, Kaiser T. Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver


Berenguer J, Álvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al.. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with


Boerekamps A, Vanwolleghem T, Van Der Valk M. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). J Hepatol. 2019;70(3):554-557.


Coyle C, Moorman AC, Bartholomew T. The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA. Hepatology. 2019;.


Dieperink E, Ho SB, Heit S, Durfee JM, Thuras P, Willenbring ML. Significant reductions in drinking following brief alcohol


Garrison KL, German P, Mogalian E, Mathias A. The drug-drug interaction potential of antiviral agents for the treatment of
chronic hepatitis C infection. Drug Metab Dispos. 2018;46(8):1212-1225.


German P, Pang P, West S, Han LL, Sajwani K, Mathias A. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract 06]. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 19-21; Washington DC. 2014;


Harrison GI, Murray K, R G. The hepatitis C awareness through to treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction. 2019;


Lange B, Roberts T, Cohn J. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17(Suppl 1):693.


Lawitz EJ, Gane EJ, Pearlman B, Tam E, Gheshiere W, Guyader D, et al. Efficacy and safety of 12 wks vs 18 wks of treatment w/ GRZ and ELB w/ or without RBV for HCV GT1 infection in previously untreated pts w/ cirrhosis and pts w/ previous null response w/ or without cirrhosis (C-WORTHY), randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-86.

Lawitz E, Landis C, Maliakkal B. Safety and efficacy of treatment with once daily ledipasvir/sofo mensenir (90/400 mg) for 12 weeks in genotype 1 HCV infected patients with severe renal impairment. The Liver Meeting. Boston, MA; 2017.


Li J, Gordon SC, Rupp LB. Sustained virological response to hepatitis C treatment decreases the incidence of


Naganuma A, Chayama K, Notsumata K. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol. 2019;


Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with endstage renal disease on haemodialysis or GFR


Newsum AM, Stolte IG, van der Meer JTM. Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22(21):30540.


Nolan S, Lima VDias, Fairbairn N, Kerr T, Montaner J, Grebely J, et al. The impact of methadone maintenance therapy on...


12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure. Gastroenterology. 2017;152(5):S1057.


Puoti M, Foster G, Wang S. High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir:


Reau N, Kwo PY, Rhee S. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1-6 Infection. In EASL International Liver Meeting, April. 2017.


Information sheet on naltrexone therapy [Internet]. Substance Abuse and Mental Health Services Administration; 2019. https://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone


Selph S, Chou R. Impact of contacting study authors on systematic review conclusions: diagnostic tests for hepatic fibrosis. 2014.


Takehara T, Sakamoto N, Nishiguchi S. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-


Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.

Tice JA, Chahal HS, Ollendorf DA. Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1 summary of California technology assessment forum report. JAMA Internal Medicine. 2015;175(9):1559-1560.


U.S. Congressional Budget Office. Prescription drug pricing in the private sector. 2015.


Walley AY, Xuan Z, Hackman HH. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346.


